Nanoparticle delivery of transition-metal chelators to the Brain: Oxidative stress will never see it coming!

CNS and Neurological Disorders - Drug Targets

Volumn 11, Issue 1, 2012, Pages 81-85

  Bonda, David J ^a   Liu, Gang ^b   Men, Ping ^b   Perry, George ^a,c   Smith, Mark A ^a   Zhu, Xiongwei ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c University of San Antonio   (United States)

Author keywords

Alzheimer disease; Amyloid beta; Chelator; Nanoparticle; Oxidative stress; Transition metal

Indexed keywords

CHELATING AGENT; COPPER; DEFEROXAMINE; IRON; NANOPARTICLE;

ALZHEIMER DISEASE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN; CELL DEATH; CHELATION THERAPY; DISEASE COURSE; DRUG DELIVERY SYSTEM; DRUG MECHANISM; ENDOCYTOSIS; HUMAN; HYDROPHILICITY; MOLECULAR WEIGHT; NONHUMAN; OXIDATIVE STRESS;

EID: 84860336238     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/187152712799960709     Document Type: Article

References (59)

1. Smith, M.A.; Hirai, K.; Hsiao, K.; Pappolla, M.A.; Harris, P.L.; Siedlak, S.L.; Tabaton, M.; Perry, G. Amyloid-beta deposition in Alzheimer transgenic mice is associated with oxidative stress. J. Neurochem., 1998, 70, 2212-2215.
2. Bonda, D.J.; Lee, H.P.; Lee, H.G.; Friedlich, A.L.; Perry, G.; Zhu, X.; Smith, M.A. Novel therapeutics for Alzheimer's disease: an update. Curr. Opin. Drug Discov. Devel., 2010, 13, 235-246.
3. Ferri, C.P.; Prince, M.; Brayne, C.; Brodaty, H.; Fratiglioni, L.; Ganguli, M.; Hall, K.; Hasegawa, K.; Hendrie, H.; Huang, Y.; Jorm, A.; Mathers, C.; Menezes, P.R.; Rimmer, E.; Scazufca, M. Global prevalence of dementia: a Delphi consensus study. Lancet, 2005, 366, 2112-2117.
4. Marabini, S.; Matucci-Cerinic, M.; Geppetti, P.; Del Bianco, E.; Marchesoni, A.; Tosi, S.; Cagnoni, M.; Partsch, G. Substance P and somatostatin levels in rheumatoid arthritis, osteoarthritis, and psoriatic arthritis synovial fluid. Ann. NY Acad. Sci., 1991, 632, 435-436.
5. Smith, M.A.; Sayre, L.M.; Monnier, V.M.; Perry, G. Radical AGEing in Alzheimer's disease. Trends Neurosci., 1995, 18, 172-176.
6. Petersen, R.B.; Nunomura, A.; Lee, H.G.; Casadesus, G.; Perry, G.; Smith, M.A.; Zhu, X. Signal transduction cascades associated with oxidative stress in Alzheimer's disease. J. Alzheimers Dis., 2007, 11, 143-152.
7. Bonda, D.J.; Wang, X.; Perry, G.; Smith, M.A.; Zhu, X. Mitochondrial dynamics in Alzheimer's disease: opportunities for future treatment strategies. Drugs Aging, 2010, 27, 181-192.
8. Zhu, X.; Castellani, R.J.; Takeda, A.; Nunomura, A.; Atwood, C.S.; Perry, G.; Smith, M.A. Differential activation of neuronal ERK, JNK/SAPK and p38 in Alzheimer disease: the 'two hit' hypothesis. Mech. Ageing Dev., 2001, 123, 39-46.
9. Zhu, X.; Lee, H.G.; Perry, G.; Smith, M.A. Alzheimer disease, the two-hit hypothesis: an update. Biochim. Biophys. Acta, 2007, 1772, 494-502.
10. Zhu, X.; Raina, A.K.; Perry, G.; Smith, M.A. Alzheimer's disease: the two-hit hypothesis. Lancet Neurol., 2004, 3, 219-226.
11. Castellani, R.J.; Harris, P.L.; Sayre, L.M.; Fujii, J.; Taniguchi, N.; Vitek, M.P.; Founds, H.; Atwood, C.S.; Perry, G.; Smith, M.A. Active glycation in neurofibrillary pathology of Alzheimer disease: N(epsilon)-(carboxymethyl) lysine and hexitol-lysine. Free Radic. Biol. Med., 2001, 31, 175-180.
12. Nunomura, A.; Perry, G.; Aliev, G.; Hirai, K.; Takeda, A.; Balraj, E.K.; Jones, P.K.; Ghanbari, H.; Wataya, T.; Shimohama, S.; Chiba, S.; Atwood, C.S.; Petersen, R.B.; Smith, M.A. Oxidative damage is the earliest event in Alzheimer disease. J. Neuropathol. Exp. Neurol., 2001, 60, 759-767.
13. Su, B.; Wang, X.; Zheng, L.; Perry, G.; Smith, M.A.; Zhu, X. Abnormal mitochondrial dynamics and neurodegenerative diseases. Biochim. Biophys. Acta, 2010, 1802, 135-142.
14. Castellani, R.J.; Lee, H.G.; Siedlak, S.L.; Nunomura, A.; Hayashi, T.; Nakamura, M.; Zhu, X.; Perry, G.; Smith, M.A. Reexamining Alzheimer's disease: evidence for a protective role for amyloid-beta protein precursor and amyloid-beta. J. Alzheimers Dis., 2009, 18, 447-452.
15. Lee, H.G.; Casadesus, G.; Zhu, X.; Takeda, A.; Perry, G.; Smith, M.A. Challenging the amyloid cascade hypothesis: senile plaques and amyloid-beta as protective adaptations to Alzheimer disease. Ann. NY Acad. Sci., 2004, 1019, 1-4.
16. Lee, H.G.; Zhu, X.; Castellani, R.J.; Nunomura, A.; Perry, G.; Smith, M.A. Amyloid-beta in Alzheimer disease: the null versus the alternate hypotheses. J. Pharmacol. Exp. Ther., 2007, 321, 823-829.
17. Halliwell, B.; Gutteridge, J.M.C. In: Free Radicals in Biology and Medicine. Oxford University Press: New York, 1999.
18. Olanow, C.W. An introduction to the free radical hypothesis in Parkinson's disease. Ann. Neurol., 1992, 32(Suppl), S2-S9.
19. Kong, S.; Liochev, S.; Fridovich, I. Aluminum(III) facilitates the oxidation of NADH by the superoxide anion. Free Radic. Biol. Med., 1992, 13, 79-81.
20. Lovell, M.A.; Robertson, J.D.; Teesdale, W.J.; Campbell, J.L.; Markesbery, W.R. Copper, iron and zinc in Alzheimer's disease senile plaques. J. Neurol. Sci., 1998, 158, 47-52.
21. Sayre, L.M.; Perry, G.; Harris, P.L.; Liu, Y.; Schubert, K.A.; Smith, M.A. In situ oxidative catalysis by neurofibrillary tangles and senile plaques in Alzheimer's disease: a central role for bound transition metals. J. Neurochem., 2000, 74, 270-279.
22. Sayre, L.M.; Perry, G.; Smith, M.A. Redox metals and neurodegenerative disease. Curr. Opin. Chem. Biol., 1999, 3, 220-225.
23. Smith, M.A.; Harris, P.L.; Sayre, L.M.; Perry, G. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc. Natl. Acad. Sci. USA, 1997, 94, 9866-9868.
24. Hardy, J. Alzheimer's disease: the amyloid cascade hypothesis: an update and reappraisal. J. Alzheimers Dis., 2006, 9, 151-153.
25. Hardy, J.A.; Higgins, G.A. Alzheimer's disease: the amyloid cascade hypothesis. Science, 1992, 256, 184-185.
26. Lee, H.G.; Zhu, X.; Nunomura, A.; Perry, G.; Smith, M.A. Amyloid beta: the alternate hypothesis. Curr. Alzheimer Res., 2006, 3, 75-80.
27. Selkoe, D.J. The molecular pathology of Alzheimer's disease. Neuron, 1991, 6, 487-498.
28. Liu, G.; Men, P.; Perry, G.; Smith, M.A. Development of iron chelator-nanoparticle conjugates as potential therapeutic agents for Alzheimer disease. Prog. Brain Res., 2009, 180, 97-108.
29. Liu, G.; Men, P.; Perry, G.; Smith, M.A. Nanoparticle and iron chelators as a potential novel Alzheimer therapy. Methods Mol. Biol., 2010, 610, 123-144.
30. Kontoghiorghes, G.J. New concepts of iron and aluminium chelation therapy with oral L1 (deferiprone) and other chelators. A review. Analyst, 1995, 120, 845-851.
31. McLachlan, D.R.; Kruck, T.P.; Lukiw, W.J.; Krishnan, S.S. Would decreased aluminum ingestion reduce the incidence of Alzheimer's disease? CMAJ, 1991, 145, 793-804.
32. Cuajungco, M.P.; Faget, K.Y.; Huang, X.; Tanzi, R.E.; Bush, A.I. Metal chelation as a potential therapy for Alzheimer's disease. Ann. NY Acad. Sci., 2000, 920, 292-304.
33. Keberle, H. The biochemistry of desferrioxamine and its relation to iron metabolism. Ann. NY Acad. Sci., 1964, 119, 758-768.
34. Richardson, D.R.; Ponka, P. Development of iron chelators to treat iron overload disease and their use as experimental tools to probe intracellular iron metabolism. Am. J. Hematol., 1998, 58, 299-305.
35. Crowe, A.; Morgan, E.H. Effects of chelators on iron uptake and release by the brain in the rat. Neurochem. Res., 1994, 19, 71-76.
36. Gassen, M.; Youdim, M.B. The potential role of iron chelators in the treatment of Parkinson's disease and related neurological disorders. Pharmacol. Toxicol., 1997, 80, 159-166.
37. Hider, R.C.; Porter, J.B.; Singh, S. The design of therapeutically useful iron chelators. In: The Development of Iron Chelators for Clinical Use; Bergeron, R.J.; Brittenham, G.M., Eds.; CRC: Boca Raton, 1994, pp. 353-371.
38. McNaught, A.D.; Wilkinson, A. IUPAC Compendium of Chemical Terminology. Royal Society of Chemistry: Cambridge, UK, 1997.
39. Olivieri, N.F.; Brittenham, G.M. Iron-chelating therapy and the treatment of thalassemia. Blood, 1997, 89, 739-761.
40. Cooper, C.E.; Lynagh, G.R.; Hoyes, K.P.; Hider, R.C.; Cammack, R.; Porter, J.B. The relationship of intracellular iron chelation to the inhibition and regeneration of human ribonucleotide reductase. J. Biol. Chem., 1996, 271, 20291-20299.
41. Hoyes, K.P.; Hider, R.C.; Porter, J.B. Cell cycle synchronization and growth inhibition by 3-hydroxypyridin-4-one iron chelators in leukemia cell lines. Cancer Res., 1992, 52, 4591-4599.
42. Lammers, M.; Follmann, H. The ribonucleotide reductases -- A unique group of metalloenzymes essential for cell proliferation. Struct. Bonding, 1983, 54, 27-91.
43. Reichard, P. Interactions between deoxyribonucleotide and DNA synthesis. Annu. Rev. Biochem., 1988, 57, 349-374.
44. Stubbe, J. Ribonucleotide reductases: amazing and confusing. J. Biol. Chem., 1990, 265, 5329-5332.
45. Gerez, C.; Fontecave, M. Reduction of the small subunit of Escherichia coli ribonucleotide reductase by hydrazines and hydroxylamines. Biochemistry (Mosc.), 1992, 31, 780-786.
46. Kreuter, J. Drug targeting with nanoparticles. Eur. J. Drug Metab. Pharmacokinet., 1994, 19, 253-256.
47. Kreuter, J. Nanoparticulate systems for brain delivery of drugs. Adv. Drug Deliv. Rev., 2001, 47, 65-81.
48. Alyautdin, R.N.; Tezikov, E.B.; Ramge, P.; Kharkevich, D.A.; Begley, D.J.; Kreuter, J. Significant entry of tubocurarine into the brain of rats by adsorption to polysorbate 80-coated polybutylcyanoacrylate nanoparticles: an in situ brain perfusion study. J. Microencapsul., 1998, 15, 67-74.
49. Kreuter, J.; Shamenkov, D.; Petrov, V.; Ramge, P.; Cychutek, K.; Koch-Brandt, C.; Alyautdin, R. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J. Drug Target, 2002, 10, 317-325.
50. Schroeder, U.; Sommerfeld, P.; Ulrich, S.; Sabel, B.A. Nanoparticle technology for delivery of drugs across the bloodbrain barrier. J. Pharm. Sci., 1998, 87, 1305-1307.
51. Alyaudtin, R.N.; Reichel, A.; Lobenberg, R.; Ramge, P.; Kreuter, J.; Begley, D.J. Interaction of poly(butylcyanoacrylate) nanoparticles with the blood-brain barrier in vivo and in vitro. J. Drug Target, 2001, 9, 209-221.
52. Borchard, G.; Audus, K.L.; Shi, F.; Kreuter, J. Uptake of surfactant-coated poly(methyl methacrylate)-nanoparticles by bovine brain microvessel endothelial cell monolayers. Int. J. Pharm., 1994, 110, 29-35.
53. Kreuter, J.; Alyautdin, R.N.; Kharkevich, D.A.; Ivanov, A.A. Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles). Brain Res., 1995, 674, 171-174.
54. Ramge, P.; Unger, R.E.; Oltrogge, J.B.; Zenker, D.; Begley, D.; Kreuter, J.; Von Briesen, H. Polysorbate-80 coating enhances uptake of polybutylcyanoacrylate (PBCA)-nanoparticles by human and bovine primary brain capillary endothelial cells. Eur. J. Neurosci., 2000, 12, 1931-1940.
55. Porter, J.B.; Gyparaki, M.; Burke, L.C.; Huehns, E.R.; Sarpong, P.; Saez, V.; Hider, R.C. Iron mobilization from hepatocyte monolayer cultures by chelators: the importance of membrane permeability and the iron-binding constant. Blood, 1988, 72, 1497-1503.
56. Liu, G.; Garrett, M.R.; Men, P.; Zhu, X.; Perry, G.; Smith, M.A. Nanoparticle and other metal chelation therapeutics in Alzheimer disease. Biochim. Biophys. Acta, 2005, 1741, 246-252.
57. Liu, G.; Men, P.; Harris, P.L.; Rolston, R.K.; Perry, G.; Smith, M.A. Nanoparticle iron chelators: a new therapeutic approach in Alzheimer disease and other neurologic disorders associated with trace metal imbalance. Neurosci. Lett., 2006, 406, 189-193.
58. Rottkamp, C.A.; Raina, A.K.; Zhu, X.; Gaier, E.; Bush, A.I.; Atwood, C.S.; Chevion, M.; Perry, G.; Smith, M.A. Redox-active iron mediates amyloid-beta toxicity. Free Radic. Biol. Med., 2001, 30, 447-450.
59. Smith, M.A.; Zhu, X.; Tabaton, M.; Liu, G.; McKeel, D.W.; Jr.; Cohen, M.L.; Wang, X.; Siedlak, S.L.; Dwyer, B.E.; Hayashi, T.; Nakamura, M.; Nunomura, A.; Perry, G. Increased iron and free radical generation in preclinical Alzheimer disease and mild cognitive impairment. J. Alzheimers Dis., 2001, 19, 363-372.